Algorithm and AI leaders
Classifier performance, architecture fit, and evaluation design.
Discuss licensing Partner pathway
A licensing process built around product fit and evidence.
The first step is not a generic sales demonstration. It is a focused discussion about the partner’s ECG environment, evaluation priorities, integration constraints, and regulatory path.
Who should engage
Qualified product, clinical, technical, and licensing teams.
Clinical and medical teams
Clinical context, workflow impact, and evidence requirements.
Regulatory and quality teams
Validation planning, intended use, documentation, and responsibilities.
Corporate development
Licensing fit, fields of use, co-development, and commercial structure.
Evaluation sequence
From fit discussion to commercial structure.
Each stage has a clear purpose and protects both the partner’s process and Arrhyva’s patent-sensitive information.
Product-fit discussion
Clarify the product category, current classifier, intended use, evidence needs, and internal decision team.
Confidentiality agreement
An NDA precedes patent-sensitive architecture, unpublished technical material, or detailed implementation review.
Technical and evidence review
Review methodology, limitations, integration assumptions, and the validation question that matters to the partner.
Partner-data evaluation
Define an appropriate dataset, success criteria, responsibilities, and reproducibility plan.
Integration planning
Map interfaces, deployment environment, clinical workflow, quality systems, and regulatory ownership.
Commercial structure
Discuss non-exclusive licensing, field-restricted structures, or co-development with legal and business counsel.
Appropriate before NDA
- High-level product fit
- Public research result and stated limitations
- Potential application categories
- General licensing and co-development availability
Shared only after NDA
- Patent-sensitive implementation details
- Deeper architecture and technical documentation
- Unpublished evaluation material
- Partner-specific integration planning
Commercial options
Discuss licensing Licensing, field-restricted structures, and co-development.
Commercial terms, exclusivity, royalties, regulatory responsibilities, and evaluation commitments remain subject to inventor and legal review.
Nothing on this website constitutes an offer, regulatory determination, or clinical claim.